Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.49 |
| ▸ | TUBB | P07437 | 5/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.49 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.49 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.49 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.49 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.49 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.49 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.49 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14626154 | 0.91 | NOTUM (0.57) | HSD17B10KMT2AMEN1NOTUMTUBB4A | |
| SCHEMBL1177124 | 0.80 | ALDH1A1 (0.58) | KMT2AMEN1NOTUMPDK1PDK2 | |
| SCHEMBL2616321 | 0.78 | HSD17B10 (0.60) | HSD17B10KMT2AMEN1NOTUMTUBB4A | |
| SCHEMBL4754558 | 0.76 | NOTUM (0.46) | KMT2AMEN1NOTUMPDK1PDK2 | |
| SCHEMBL13993091 | 0.76 | NOTUM (0.46) | KMT2AMEN1NOTUMSRD5A1 | |
| SCHEMBL7261315 | 0.76 | HSD17B10 (0.62) | HSD17B10KMT2AMEN1NOTUMTUBB4A | |
| SCHEMBL21524785 | 0.76 | HSD17B10 (0.58) | HSD17B10KMT2AMEN1NOTUMTUBB4A | |
| SCHEMBL13531815 | 0.76 | MEN1 (0.66) | HSD17B10KMT2AMEN1NOTUMPDK1 | |
| SCHEMBL8554737 | 0.76 | ALDH1A1 (0.66) | HSD17B10KMT2AMEN1NOTUMTUBB4A | |
| SCHEMBL1177380 | 0.76 | HSD17B10 (0.58) | HSD17B10KMT2AMEN1NOTUMTUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8168634-B2 | Thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-05-01 | — | — | US | disclosed |
| EP-1881827-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-7888344-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2011-02-15 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| US-20100298310-A1 | Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-11-25 | — | — | US | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| EP-2084155-A1 | THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-08-05 | — | — | EP | disclosed |
| WO-2009071888-A1 | PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| EP-2029570-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008047109-A1 | THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-04-24 | — | — | WO | disclosed |
| EP-1881827-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2008-01-30 | — | — | EP | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007141504-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2006114606-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | HSD17B10 2438/4885KMT2A 2966/4885MEN1 1461/4885 |
| US-20100298310-A1 | Thiazole Derivatives as Kinase Inhibitors | TEC, BTK, PI4KA | HSD17B10 2642/4885KMT2A 1926/4885MEN1 1425/4885 |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | HSD17B10 2922/4885KMT2A 2175/4885MEN1 2762/4885 |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | MAP4K2, PDPK1, DAPK2 | HSD17B10 2934/4885KMT2A 1182/4885MEN1 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.